BL0175

Phase 1Small molecule

SShanghai Best-Link Bioscience, LLC

BL0175 is one of 33 small molecule programs targeting Postmenopausal Women. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Postmenopausal WomenNot yet recruiting

Metastatic CancerRecruiting

Postmenopausal WomenPhase 1

Not yet recruiting

Metastatic CancerPhase 1

Recruiting

Competition

Competitive Landscape

29 competitors in Metastatic Cancer

#DrugCompanyPhaseTrials

Avastin

Roche

Approved

8 2

Keytruda

Merck & Co.

Phase 2

5 3

Opdivo

Bristol-Myers Squibb

Phase 2

5 4

Cytoxan

BBaxter Healthcare Corporation

Phase 2

15 5

Proleukin

IIovance Biotherapeutics, Inc.

Phase 2

14 6

Yervoy

Bristol-Myers Squibb

Phase 2

2 7

Lenvima

Eisai

Phase 2

1 8

Talzenna

Pfizer

Phase 2

1 9

Zejula

GGlaxo Dba Glaxosmithkline

Phase 2

1 10

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Postmenopausal Women

NCT07366632

Q4 2027

Phase 1Recruiting

Metastatic Cancer

NCT06738966

Clinical

Trials by Indication[1]

Metastatic Cancer1 trial

A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer

Recruiting·SShanghai Best-Link Bioscience, LLC·Phase 1·NCT06738966·9 enrolled

Postmenopausal Women1 trial

A Study of Single Dose of BL0175 in Postmenopausal Women

Not yet recruiting·SShanghai Best-Link Bioscience, LLC·Phase 1·NCT07366632·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BL0175. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BL0175 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BL0175. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Best-Link Bioscience, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SShanghai Best-Link Bioscience, LLC

BL0175

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Trials by Indication[1]

Metastatic Cancer1 trial

Postmenopausal Women1 trial

References

Drug Info

Quick Facts

Related News